Trial Profile
A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Sym-023 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Symphogen
- 21 Sep 2020 Results of three phase1, first-in-human studies (NCT03311412, NCT03489369; NCT03489343) assessing effect Sym021, Sym022, and Sym023 alone and Sym021 in combination with either Sym022 or Sym023, presented at the 45th European Society for Medical Oncology Congress.
- 08 Sep 2020 Status changed from active, no longer recruiting to completed.
- 09 Jan 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Jun 2020.